Sandoz Canada Inc.

Meetings over time

• Aug 20252 meetingsPaul Moen, Sandenga Yeba
  Aug 2025: 2 meetings, with Paul Moen, Sandenga Yeba
• Sep 20252 meetingsSandenga Yeba, Paul Moen, Manuela Tomic, Cédrick Devedeux Delorme
  Sep 2025: 2 meetings, with Sandenga Yeba, Paul Moen, Manuela Tomic, Cédrick Devedeux Delorme
• Oct 20250 meetings
  Oct 2025: 0 meetings
• Nov 20253 meetingsRodrigo Arancibia, Manuela Tomic
  Nov 2025: 3 meetings, with Rodrigo Arancibia, Manuela Tomic
• Dec 20250 meetings
  Dec 2025: 0 meetings
• Jan 20261 meetingSandenga Yeba
  Jan 2026: 1 meeting, with Sandenga Yeba
• Feb 20260 meetings
  Feb 2026: 0 meetings
• Mar 20262 meetingsMélanie Joly, Paul Moen, Manuela Tomic, Marjorie Michel, Sandenga Yeba
  Mar 2026: 2 meetings, with Mélanie Joly, Paul Moen, Manuela Tomic, Marjorie Michel, Sandenga Yeba
• Apr 20262 meetingsJustine Frame, Manuela Tomic, Ian Burke Cameron
  Apr 2026: 2 meetings, with Justine Frame, Manuela Tomic, Ian Burke Cameron
• May 20261 meetingJustine Frame, Sandenga Yeba
  May 2026: 1 meeting, with Justine Frame, Sandenga Yeba

Hover or focus a month to see who was met.

What they lobby about

• Health13
• Budget11
• Economic Development11
• Industry3
• Science and Technology3

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Who they met

Innovation, Science and Economic Development Canada (ISED) (12) · Health Canada (HC) (8)

In their own words

• "In line with current government priorities, ensure greater harmonisation of policies from the Departments of Innovation, Science and Economic Development and Health Canada's regulatory efficiency and streamlining efforts with regard to drug regulation and approval, particularly under the Food and Drugs Act for pharmaceutical products offered for sale in Canada. The objective is to make quality generic and biosimilar medicines available more quickly in Canada, in the interests of patients and the provinces and territories, while generating substantial savings for private and public plans."
• Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.
• As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.